<DOC>
	<DOC>NCT00063102</DOC>
	<brief_summary>The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.</brief_summary>
	<brief_title>A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Inclusion Criteria Stage IIIB or IV breast cancer. Recurrent tumor after or while on taxane therapy (taxol or taxotere). Able to tolerate normal activities of daily living. Adequate bone marrow, kidney and liver function. Exclusion Criteria Pregnant or breast feeding. No antitumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT751 administration.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>